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http://arthritis-research.com/content/16/5/451RESEARCH ARTICLE Open AccessCost-utility of cognitive behavioral therapy versus
U.S. Food and Drug Administration recommended
drugs and usual care in the treatment of patients
with fibromyalgia: an economic evaluation
alongside a 6-month randomized controlled trial
Juan V Luciano1,2,3*, Francesco D’Amico4, Marta Cerdà-Lafont1, María T Peñarrubia-María2,5, Martin Knapp2,4,
Antonio I Cuesta-Vargas2,6, Antoni Serrano-Blanco1,2 and Javier García-Campayo2,7Abstract
Introduction: Cognitive behavioral therapy (CBT) and U.S. Food and Drug Administration (FDA)-recommended
pharmacologic treatments (RPTs; pregabalin, duloxetine, and milnacipran) are effective treatment options for
fibromyalgia (FM) syndrome and are currently recommended by clinical guidelines. We compared the cost-utility
from the healthcare and societal perspectives of CBT versus RPT (combination of pregabalin + duloxetine) and usual
care (TAU) groups in the treatment of FM.
Methods: The economic evaluation was conducted alongside a 6-month, multicenter, randomized, blinded, parallel
group, controlled trial. In total, 168 FM patients from 41 general practices in Zaragoza (Spain) were randomized to
CBT (n = 57), RPT (n = 56), or TAU (n = 55). The main outcome measures were Quality-Adjusted Life Years (QALYs,
assessed by using the EuroQoL-5D questionnaire) and improvements in health-related quality of life (HRQoL,
assessed by using EuroQoL-5D visual analogue scale, EQ-VAS). The costs of healthcare use were estimated from
patient self-reports (Client Service Receipt Inventory). Cost-utility was assessed by using the net-benefit approach
and cost-effectiveness acceptability curves (CEACs).
Results: On average, the total costs per patient in the CBT group (1,847€) were significantly lower than those in
patients receiving RPT (3,664€) or TAU (3,124€). Patients receiving CBT reported a higher quality of life (QALYs and
EQ-VAS scores); the differences between groups were significant only for EQ-VAS. From a complete case-analysis
approach (base case), the point estimates of the cost-effectiveness ratios resulted in dominance for the CBT group
in all of the comparisons performed, by using both QALYs and EQ-VAS as outcomes. These findings were confirmed
by bootstrap analyses, net-benefit curves, and CEACs. Two additional sensitivity analyses (intention-to-treat analysis
and per-protocol analysis) indicated that the results were robust. The comparison of RPT with TAU yielded no clear
preference for either treatment when using QALYs, although RPT was determined to be more cost-effective than
TAU when evaluating EQ-VAS.
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Conclusions: Because of lower costs, CBT is the most cost-effective treatment for adult FM patients. Implementa-
tion in routine medical care would require policymakers to develop more-widespread public access to trained and
experienced therapists in group-based forms of CBT.
Trial registration: Current Controlled Trials ISRCTN10804772. Registered 29 September 2008.Introduction
Fibromyalgia (FM) is a complex clinical entity that is
currently considered to be part of the spectrum of cen-
tral sensitivity syndromes [1]. FM was defined in 1990 as
the presence of chronic widespread pain lasting for more
than 3 months and patient reports of tenderness in at
least 11 of 18 defined tender points when digitally pal-
pated with approximately 4 kg per unit area of force [2].
In May 2010, the American College of Rheumatology
(ACR) published preliminary diagnostic criteria that elimi-
nate the tender-point examination [3].
According to a recent review [4], the prevalence esti-
mates of FM in the general population have ranged from
approximately 1% to 11%, with women being consider-
ably more vulnerable to FM than men. The prevalence
of the syndrome increases with age until approximately
the sixth decade and decreases thereafter.
Several studies have analyzed the health-care and soci-
etal burdens associated with FM in industrialized coun-
tries [5,6]. Leadley and colleagues [5] reviewed 10 cost
and 29 prevalence studies and noted that among
chronic-pain conditions, FM syndrome had the highest
unemployment rate (6%), highest claim rate for incap-
acity benefits (from 11.9% to 29.9%), and greatest num-
ber of days absent from work (from 21 to 73).
Currently, no curative treatments are available for pa-
tients with FM. Both pharmacologic and nonpharmaco-
logic approaches are used by clinicians to alleviate the
constellation of FM symptoms and to improve patients’
functioning. To date, only the following medications
have been approved by the US Food and Drug Adminis-
tration (FDA) for FM pain: pregabalin (second-generation
anticonvulsant), approved in 2007; duloxetine (SNRI), ap-
proved in 2008; and milnacipran (SNRI), approved in
2009. In contrast, the European Medicines Agency (EMA)
refused to approve these medications, based on a benefit-
risk assessment [7-9].
A recent meta-analysis [9] of eight RCTs that focused
on the effectiveness of anticonvulsants yielded the follow-
ing results: a slight reduction of pain and sleep problems
with pregabalin compared with placebo after 13 weeks of
treatment, on average. The results suggested that the ef-
fects of pregabalin in reducing fatigue, depression, and
anxiety and in improving HRQoL were limited. Addition-
ally, the reported side effects from the use of pregabalin
included dizziness.Häuser and colleagues [10] revised and performed a
meta-analysis of 10 studies to ascertain the benefits and
harms of FDA-recommended SNRIs compared with a
placebo when treating FM symptoms in adults. The re-
sults suggested that duloxetine and milnacipran only
had a small incremental effect over the placebo in redu-
cing pain. The effect on fatigue was not substantial, and
both were inferior to the placebo for reducing sleep
problems. Finally, Nüesch et al. [11] performed a net-
work meta-analysis of randomized trials in patients with
FM that evaluated the effects of pharmacologic and non-
pharmacologic interventions recommended by FM guide-
lines. The authors found statistically significant advantages
of SNRIs and pregabalin over placebo on pain and quality
of life, although these benefits were not clinically relevant.
They concluded that benefits of pharmacologic treatments
in FM were of questionable clinical relevance, and evi-
dence for the benefits of nonpharmacologic interventions
is limited. This conclusion about the modest effectiveness
of pharmacologic and nonpharmacologic approaches
might be generalized to all chronic pain conditions [12,13].
Concerning nonpharmacologic interventions, Bernardy
et al. [14] performed a meta-analysis of 23 studies that
indicated that treatment with CBTs provided a small in-
cremental benefit over control interventions in reducing
pain, negative mood, and disability at end of treatment
and at long-term follow-up (median, 6 months) in pa-
tients with FM. Overall, the RCTs had poor quality, but
the sensitivity analyses demonstrated that the results
were robust against the risks of bias.
Although the aforementioned meta-analyses provided
data about the effectiveness of specific pharmacologic
and nonpharmacologic treatments for FM, evidence is
lacking regarding their cost-effectiveness [15]. In the
current worldwide context of economic crisis, decision-
makers are faced with health-care budget constraints
and must prioritize their expenditures on the pharmaco-
logic or nonpharmacologic option that is the most cost
effective for the treatment of a particular patient group.
A cost-effectiveness analysis can help to resolve the di-
lemma of which available treatment generates the max-
imal health benefits for the health care system and for
society as a whole.
Two studies have examined the cost-effectiveness of
pregabalin in the treatment of FM, one from a UK per-
spective [16] and one from a US perspective [17]. Choy
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450 mg of pregabalin in the treatment of FM compared
with placebo, duloxetine, gabapentin, tramadol, and ami-
triptyline. Pregabalin was found to be cost-effective at a
threshold of £30,000 per QALY gained compared with
the other treatment options or placebo in approximately
60% of patients participating in FM clinical trials. Prega-
balin, 450 mg, was consistently more cost-effective than
pregabalin, 300 mg. More recently, Lloyd et al. [17] rep-
licated the analysis, but from the US perspective. Prega-
balin was less costly than placebo for both direct and
indirect costs. In this model, pregabalin, 450 mg, was
consistently more cost-effective than pregabalin, 300 mg.
Beard et al. [18] carried out an economic evaluation of
the cost-effectiveness of 60 mg/day duloxetine. The ana-
lyses revealed that it might be more cost-effective to
consider duloxetine as a second-line treatment option,
after failure on tricyclic antidepressants.
Among nonpharmacologic treatments [19-22], only psy-
choeducation [22] has shown evidence of cost-effectiveness.
Luciano et al. [22] found that usual care complemented
by a 9-week psychoeducation program was effective and
cost-effective for FM within a general-practice setting and
at a 12-month follow-up. Only Alda et al. [23] compared
the effectiveness of CBT versus FDA-recommended phar-
macologic treatment (RPT, pregabalin + duloxetine in case
of comorbid major depression) and treatment-as-usual
(TAU). The 6-month follow-up evaluation revealed that
CBT was more effective than RPT, taking a wide range of
clinical variables into account.a In a recent review [24], it
was highlighted that a web-based CBT program (“Living
Well with Fibromyalgia”) demonstrated effect sizes in pain
and physical functioning that were comparable or superior
to the FDA-approved medications. The numbers needed
to treat were 7.2, 19.0, and 8.6 for duloxetine, milnacipran,
and pregabalin, respectively; but only 5 for the web-based
CBT program.
In the present work, we extend our previously re-
ported findings of CBT in FM [23] by comparing, for
the first time, the 6-month healthcare and societal costs
associated with CBT, FDA-RPT, and TAU, as well as the
6-month cost-effectiveness of CBT, FDA-RPT, and TAU
in terms of gains in QALYs and increases in HRQoL.
Methods
A detailed description of the RCT protocol and the ef-
fectiveness results can be reviewed elsewhere [23,25]b.
This study was performed in accordance with the ethical
standards established in the 1964 Declaration of Helsinki
and its subsequent updates and established in the Dec-
laration of Madrid of the World Psychiatric Association.
The study protocol was approved through the ethical
review board of the Aragon Health Sciences Institute
(IACS), Aragon, Spain (February 2007; ETES numberPI07/90959). The IACS is the center responsible for re-
search and knowledge management in Biomedicine and
Health Sciences in the public Aragon Health System. All
participants provided written informed consent before the
commencement of any study activities or procedures.
This study followed the Initiative on Methods, Measure-
ment, and Pain Assessment in Clinical Trials (IMMPACT)
recommendations for chronic pain clinical trials [26]; the
Consolidated Standards of Reporting Trials (CONSORT)
recommendations for randomized, controlled trials [27];
and the Consolidated Health Economic Evaluation Report-
ing Standards (CHEERS) statement [28] [see Additional
file 1].
Design
The study was a 6-month, multicenter, randomized,
parallel-group, controlled trial in which patients with FM
were recruited from any of the 41 primary healthcare cen-
ters in the city of Zaragoza (Aragon, Spain) and randomly
assigned to one of three study groups (ratio, 1:1:1): CBT
(n = 57), RPT (n = 56), and TAU at the primary health care
level (n = 55). The two evaluators (clinical psychologists)
were blinded to patients’ treatment-group assignments.
Patients considered for inclusion were adults from 18
to 65 years of age who were able to understand and read
Spanish, fulfilled the 1990 ACR classification criteria [2]
for FM, had undergone no psychological treatment during
the preceding 2 years, were receiving no pharmacologic
treatment at that time or were willing to discontinue it for
2 weeks before the start of the study, and had signed an
informed-consent statement. Those excluded were pa-
tients with severe axis I psychiatric disorders (dementia,
schizophrenia, paranoid disorder, and alcohol and/or drug
abuse); patients with severe axis II psychiatric disorders or
other medical conditions that, from the clinician’s point of
view, prevented the patient from following the treatment
protocol; women who were pregnant or nursing; and those
who declined to participate.
Aragon is one of the 17 regions or “autonomous com-
munities” of Spain. As a consequence of a devolution
process that started in 1981, the autonomous communi-
ties have full governance of health and social care. Health
care is publicly financed, with universal coverage. The
Aragon Health Care System covers all of the region’s terri-
tory. (The region of Aragon has more than 1,200,000 in-
habitants). Social care is also covered for people with a
functional dependency due to severe disability.
Interventions
An outline of the nine CBT group sessions is displayed in
Table 1. The CBT intervention was highly structured and
performed in a group-based format (maximum of eight
patients per group). Throughout the CBT treatment, ex-
tensive emphasis occurred on putting into practice skills
Table 1 Session outlines for the Cognitive Behavioral
Therapy (CBT) group treatment protocol
Session Group CBT
1 Discussing the connection between stress and pain
2 Identification of automated, negative thoughts
3 Evaluation of automated, negative thoughts
4 Challenging the automatic, negative thoughts and
constructing alternatives
5 Nuclear beliefs
6 Nuclear beliefs about pain
7 Changing coping strategies
8 Coping with ruminations-obsessions-worrying. Session focused
on pain catastrophizing.
9 Expressive writing and assertive communication
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homework tasks with the goal of fostering practice of the
skills outside of the sessions. It was considered essential
that FM patients practice skills outside of sessions, as part
of their daily lives, so they could become more comfort-
able with new, unfamiliar behaviors and ways of thinking,
learn what types of coping strategies work best for them,
and, important, have the opportunity to identify auto-
matic, negative thoughts and cognitive errors, and to re-
view problems in implementing skills outside the safe
environment of the CBT group.
Trained clinicians at the Torrero health center adminis-
tered the intervention. Random sessions were audio-
recorded to confirm that the CBT program was exclusively
delivered. Although CBT is usually considered a com-
plement (adjuvant) to usual medical treatment, not a sub-
stitute for it, we decided to test its effectiveness as a
stand-alone intervention. Therefore, only minor co-
medication was allowed in the CBT group (occasionally
minor analgesics), but no pregabalin, gabapentin, opioids,
or antidepressants were permitted.
Regarding the RPT, pregabalin (300 to 600 mg/day)
and duloxetine (60 to 120 mg/day in case of comorbid
major depression) was administered to FM patients. One
psychiatrist monitored RPT throughout the study.
Finally, the TAU group received the standard care de-
livered by general practitioners (GPs) at their primary
healthcare centers. To improve this treatment, GPs re-
ceived the Guide for the Treatment of Fibromyalgia in
Primary Care, which is edited and distributed by the
Aragonese Health Service. In Spanish primary health
care, the treatment administered to FM patients is
mainly pharmacologic and is adjusted to the symptom-
atic profile of the individual. In addition, counseling re-
garding aerobic exercise adjusted to patients’ physical
levels is usually provided. TAU means that GPs selected
a pharmacologic treatment and the frequency of patient
visits that they considered adequate. Neither the RPTpatients nor the TAU patients received any psychological
intervention during the 6-month trial.
A comprehensive summary and evaluation of the study
was recently published by Bernardy and colleagues [14],
who assigned 7 points to the trial by using Yates rating
scale [29], a score that indicates a high treatment quality.
Figure 1 illustrates the flow of participants through the
economic evaluation, and Table 2 shows the baseline
sociodemographic and clinical characteristics of the par-
ticipants by treatment group. No statistically significant
differences were noted between the three study condi-
tions in any sociodemographic or clinical variable at
baseline.
Instruments
The participants completed the following assessments as
part of a paper-and-pencil battery of measures:
The Sociodemographic questionnaire collected infor-
mation on the following variables: gender, date of birth,
marital status, living arrangements, education level, and
employment status (which was asked at all assessment
time points).
The MINI Neuropsychiatric Interview (M.I.N.I v5.0)
[30,31] is a brief, structured diagnostic interview de-
signed to assess DSM-IV and ICD-10 psychiatric disor-
ders. The M.I.N.I. is the most widely used psychiatric
structured diagnostic interview in the world. In the
present study, we specifically assessed the presence of
Axis I psychiatric disorders (dementia, schizophrenia,
paranoid disorder, alcohol and/or drug use disorders).
The EuroQoL-5D questionnaire (EQ-5D) [32] is a
widely used health-related quality-of-life instrument with
a non-disease-specific classification system composed of
two parts: Part 1 is a self-reported description of health
problems according to a five-dimensional classification
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression). Patients mark one of three levels of
severity (1 = no problems, 2 = some/moderate problems,
and 3 = severe/extreme problems) in each dimension.
The time frame is the day of responding. Combinations
of these categories define a total of 243 (35) different
health states. Part 2 records the current subject's health
on a Visual Analogue Scale (VAS); it consists of a visual
scale graded from 0 to 100, in which the respondent can
self-report the current health status, with 100 being the
best imaginable health level. The EQ-5D has already
been demonstrated to be a valid and reliable tool to as-
sess health outcomes of the Spanish population [33].
The Client Service Receipt Inventory–Spanish version
(CSRI) [34] variation used in this study was designed to
collect retrospective data on medication and service
receipt.
Medication use. A profile of the patient's use of some
prescribed medications (analgesics, short- and long-acting
Figure 1 Flow chart of the economic evaluation.
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requested, including the name of the drug, the prescriber,
the dosage level, the total number of prescription days for
the drug, the daily dosage consumed, the reasons for
changing the drug, and adherence.
Service receipt. The main categories were: emergency
service (total visits), general medical in-patient hospital
admissions (total days), and outpatient health care ser-
vices (total visits to GP, nurse, social worker, psycholo-
gist, and other community health care professionals).
Each service was recorded as being provided by the pub-
lic or by the private sector. Patients were also asked
about the type and number of diagnostic tests adminis-
tered. The CSRI was administered on two occasions with
equal time frames: at baseline and at a 6-month follow-
up; at both occasions, the previous 6 months were
reviewed. Empiric evidence indicates that data obtained
by the self-report has equal validity to register-collected
data [35].Statistical analyses
Description of the costing procedure
Costs were estimated from the healthcare and societal
perspectives during the 6 months of follow-up. Direct
health care costs were calculated by adding the costs
derived from medication consumption, medical tests,
use of health-related services, and cost of the staff
running the CBT intervention. The cost of medication
was calculated by determining the price per milligram
according to the Vademecum International (Red Book;
edition 2011) and included the value-added tax. The
total costs of medications were calculated by multiply-
ing the price per milligram by the daily dosage used
(in milligrams) and the number of days that the treat-
ment was received.
The main source of the unit-cost data for medical tests
and health services use was the SOIKOS database of
health care costs [36]. The SOIKOS database contains
information about Spanish healthcare service costs and
Table 2 Baseline sociodemographic and clinical characteristics of the study participants by treatment group
Sociodemographic variables CBT RPT TAU P
(n =57) (n =56) (n =55)
Gender, females, n (%) 54 (94.7%) 52 (92.9%) 53 (96.4%) 0.71
Mean age, years (±SD) 46.35 (6.71) 47.12 (6.25) 47.04 (6.53) 0.79
Marital status, n (%) 0.99
Married or in a relationship 40 (70.2%) 40 (71.4%) 37 (67.3%)
Single 9 (15.8%) 9 (16.1%) 10 (18.2%)
Separated or divorced 8 (14%) 7 (12.5%) 8 (14.5%)
Widowed 0 (0%) 0 (0%) 0 (0%)
Ethnic group, n (%) 1.00
European 57 (100%) 56 (100%) 55 (100%)
Living arrangement, n (%) 0.99
Living alone 4 (7.0%) 4 (7.1%) 6 (10.9%)
Living with spouse or partner 8 (14.0%) 9 (16.1%) 8 (14.5%)
Living with offspring and/or spouse/partner 34 (59.6%) 30 (53.6%) 31 (56.4%)
Living with other relatives 5 (8.8%) 7 (12.5%) 5 (9.1%)
Other 6 (10.5%) 6 (10.7%) 5 (9.1%)
Educational level, n (%) 0.81
Illiterate 0 (0%) 0 (0%) 0 (0%)
Primary school 23 (40.4%) 23 (41.1%) 28 (50.9%)
Secondary school 23 (40.4%) 22 (39.3%) 18 (32.7%)
University 11 (19.3%) 11 (19.6%) 9 (16.4%)
Employment status, n (%) 0.99
Unemployed 19 (29.8%) 15 (26.8%) 15 (27.3%)
Paid employment 9 (15.8%) 11 (19.6%) 9 (16.4%)
On sick leave from paid employment 13 (22.8%) 12 (21.4%) 14 (25.5%)
Retired/pensioner 7 (12.3%) 6 (10.7%) 8 (14.5%)
Permanent disability 11 (19.3%) 12 (21.4%) 9 (16.4%)
Income 0.40
<MS (600€/month) 15 (26.3%) 15 (26.8%) 27 (49.1%)
1 to 2 MS 24 (42.1%) 23 (41.1%) 20 (36.4%)
>2 to 4 MS 18 (31.6%) 18 (32.1%) 8 (14.5%)
>4 MS 0 (0) 0 (0) 0 (0)
Clinical variables
Mean years since FM diagnosis (±SD) 12.91 (7.15) 11.23 (3.85) 11.69 (4.02) 0.22
Preference for psychotherapy, n (%) 28 (49.1%) 26 (46.4%) 27 (49.1%) 0.95
Comorbid major depressive disorder, n (%) 27 (47.4%) 26 (46.4%) 30 (54.5%) 0.65
Sexual abuse, n (%) 4 (7.0%) 7 (12.5%) 11 (14.5%) 0.43
Currently engaged in litigation, n (%) 17 (29.8%) 12 (21.4%) 16 (29.1%) 0.54
CBT, cognitive behavioral therapy; MS, minimum salary; RPT, recommended pharmacologic treatment; TAU, treatment as usual.
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consists of approximately 18,000 entries. The calculation
of the total cost of CBT intervention per patient was
based on the price per hour of a clinical psychologist,
established by the Official College of Psychologists of
Spain. Indirect costs (lost productivity): Lost productivity
was calculated by using the human capital approach,
which involves multiplying the minimum daily wage inSpain for 2011 by the number of days of sick leave, as
reported by each patient.
Finally, total costs were calculated by adding the direct
and indirect costs. Unit costs are expressed in Euros (€)
based on 2011 prices. Table 3 shows the unit costs of
healthcare resources. The time horizon was less than a
year; therefore, it was not necessary to apply a discount
factor to the costs.
Table 3 Unit costs used in the calculations of direct healthcare costs and indirect costs (year 2011 values in €)
Type of use Unit costs
Costs in the health care system
(public/private)
General practitioner 10.5/27.5
Nurse or psychiatric nurse 10.0/25.4
Social worker 14.9/25.4
Psychologist 70.6/70.6
Psychiatrist 42.9/42.9
Other medical specialists 51.1/51.1
Hospital emergency visits 155.5
Hospital stay 617.5
Diagnostic tests (range) 4.3 to 434.6
Pharmacologic treatment Depending on type
and dose
Productivity losses Absenteeism from work (minimum and medium daily wage) 21.4 to 62.7
CBT costs Cost of the group intervention per session (eight patients/group; nine sessions) 240
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Patients described their quality of life by using the EQ-5D
questionnaire, which represents a preferable alternative
when implementing economic evaluations with a societal
perspective. Utility scores obtained from the questionnaire
are used to rate patients’ quality of life on a scale from 0
(as bad as death) to 1 (perfect health). Negative values are
possible and indicate a health state that is “worse than
death”. QALYs were calculated on the basis of these scores
by using the Spanish tariffs of EQ-5D [37]. Along with
EQ-5D utility scores, scores recorded on the EQ VAS were
also used as an outcome for the analysis.
Cost-utility analysis
Cost-utility was explored through the calculation of incre-
mental cost-effectiveness ratios (ICERs), defined as the ra-
tio between incremental costs and incremental effects
measured on QALYs or EQ VAS [38]. QALYs were ap-
proximated by using the area-under-the-curve technique.
We estimated incremental marginal costs and incre-
mental effects with the SUR (seemingly unrelated regres-
sion) model by using STATA. Cost and outcome measures
were therefore included in a bivariate system that imple-
mented a regression of costs and QALYs (or EQ VAS) on
treatment allocations (that is, whether they were assigned
to CBT, RPT, or TAU).
The regressions controlled also for the following vari-
ables at baseline: age, gender, marital status, education
level, living arrangement, employment status, minimum
wage, duration of the illness (in years) since the first
diagnosis, baseline costs, and baseline outcome, depend-
ing on the equation considered.
Estimates were run by using 1,000 bootstrap replica-
tions to address a possible skewedness in the distribu-
tion of the dependent variables [39]. By using a series of
hypothetical values for willingness-to-pay (λ) for one
additional unit of outcome (QALY), net-benefits (NBs)were calculated. We plotted NB curves to compare the
Net Monetary Benefit (NMB; y-axis) obtained by the
three alternative interventions with the corresponding
willingness-to-pay (WTP; x-axis).
Cost-effectiveness acceptability curves (CEACs) will
also be plotted when necessary [40]. CEACs display the
probability that the intervention is cost-effective, given a
varying threshold for the willingness to pay for each
QALY gained. The curves obtained incorporate the un-
certainty that exists around the estimates of incremental
costs and incremental effects associated with the inter-
vention [41].
First, we did a complete case analysis without the 16 FM
patients who were lost at 6-month follow-up. Second, the
cost-utility analysis was repeated after an intention-to-
treat (ITT) approach (first sensitivity analysis). The way in
which missing data are handled is of crucial importance
when assessing the results of economic evaluations. For
the 6-month follow-up evaluation, a small number of
missing values (9.5%) were imputed. We assumed data to
be missing at random (MAR). Multiple imputation methods
according to the chained-equations approach were used to
impute missing values for the EQ-5D domains and for the
costs of the nonresponders at 6 months [42-45]. The im-
putation model, run on 10 imputed datasets, included
important sociodemographic and prognostic variables as-
sociated with the outcome variables and dropouts.
Finally, we also performed a per-protocol analysis (PPA;
2nd sensitivity analysis) in which the 14 FM patients who
did not attend the nine CBT sessions were excluded.
All statistical analyses were performed by using STATA
version 13.0 (Stata Corp. College Station, TX, USA).
Results
Costs
In Table 4, we display descriptive statistics for different
groups of costs, along with the adjusted and unadjusted
Table 4 Summary statistics of the costs (total and disaggregated in components) and outcomes by treatment group
CBT RPT TAU Significance test
Mean SD Mean SD Mean SD
Before baseline (6 months before baseline) - N =168 n =57 n =56 n =55 P value adj. P value
Costs (€)
Primary health care services 102.7 21.9 103.1 21.5 104.3 14.5 0.87 0.99
Specialized healthcare services 1554.9 3499.8 1150.0 3113.1 1038.3 2813.4 0.67 0.55
Medical tests 49.2 113.7 48.2 103.8 48.5 101.4 1.00 0.97
Prescribed medications 475.7 876.6 563.0 1139.3 581.2 1196.7 0.83 0.80
Total direct costs 2182.4 3609.6 1864.3 3232.8 1772.3 2954.4 0.79 0.71
Total indirect costs 916.3 1415.3 741.8 1379.5 771.2 1335.5 0.77 0.81
Total costs 3098.8 3999.7 2606.1 3871.2 2543.5 3486.3 0.71 0.62
Outcomes
EQ-5D Utility score 0.40 0.26 0.40 0.27 0.38 0.27 0.93 1.00
EQ VAS 45.18 16.98 46.79 15.48 43.36 14.50 0.50 0.64
Follow-up (0 to 6 months), N =152 n =53 n =50 n =49 P-value adj. P-value
Costs (€)
Primary health care services 80.9 35.4 110.8 19.6 112.6 19.5 0.00 0.00
Specialized healthcare services 940.2 2731.7 1854.4 4109.2 1663.5 3612.7 0.32 0.01
Medical tests 44.7 115.8 67.3 119.2 65.9 110.6 0.54 0.00
Prescribed medications 33.0 55.3 828.1 356.5 530.8 322.0 0.00 0.00
Intervention CBT 271.1 24.7 0.0 0.0 0.0 0.0 0.00 0.00
Total direct costs 1,369.9 2,738.5 2,860.6 4,161.3 2,372.8 3,570.2 0.07 0.00
Total indirect costs 476.8 887.6 803.0 1,307.6 750.9 1,226.3 0.21 0.00
Total costs 1,846.7 2,942.9 3,663.7 4,539.1 3,123.7 3,952.5 0.03 0.00
Outcomes
EQ-5D Utility score 0.61 0.25 0.53 0.27 0.54 0.28 0.28 0.13
EQ VAS 59.62 15.78 57.30 14.11 52.86 14.25 0.07 0.00
QALY (based on EQ-5D utility score) 0.25 0.12 0.23 0.13 0.24 0.13 0.63 0.13
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strapped t tests (1,000 replications). None of the differ-
ences at baseline was found to be statistically significant.
The average cost of primary care services for 6-month
use was found to be approximately 100€ at baseline for
each of the treatment groups. However, although the
average cost of primary care services remained roughly
at the same level at 6 months after baseline, the use re-
lated to individuals from the CBT group diminished to
approximately 80€, whereas the use by members of the
other two groups increased to approximately 110€. The
difference at this stage was found to be significant both
with the un-adjusted and adjusted P values.
The cost of specialized health care services was found
to be higher at baseline for the CBT group (1,550€), with
the RPT (1,150€) and TAU (1,040€) groups showing
lower averages. In contrast, at the 6-month follow-up,
the cost of specialized health care services diminished to
940€ for the CBT group, whereas it increased considerably
for the RPT (1,850€) and for the TAU groups (1,660€).The adjusted difference between groups was found to be
significant.
The cost of medical tests was found to be approxi-
mately 50€ at baseline for all groups, although it in-
creased at follow-up to 67€ and 66€ for the RPT and for
the TAU groups, respectively. Both groups were found
to be significantly different at follow-up compared with
the CBT group (<45€).
The cost of prescribed medications at baseline was
found to be lower for the CBT group (475€), whereas it
was higher for the RPT (563€) and for the TAU (581€)
groups. At follow-up, the use of medications by individ-
uals in the CBT group decreased to an average of 33€,
which is attributed mainly to the nature of the interven-
tion that required individuals from this group to discon-
tinue the use of most medications. The use of medications
from the other two groups instead was increased for RPT
(828€) and was slightly reduced for TAU (530€).
Overall, the direct costs were higher for the CBT group
at baseline (2,200€) with respect to the RPT (1,864.3€) and
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cost for CBT reduced to 1,370€, whereas it increased for
RPT (2,860€) and TAU (2,370€). The difference at this
stage was found to be significant with the adjusted P value.
A similar pattern was observed for indirect costs, which
were initially slightly higher for the CBT group (approxi-
mately 900€) but were halved at follow-up (approximately
480€) to a level significantly lower than for the other two
groups (see adjusted P value). Total costs were conse-
quently lower at follow-up for the CBT group (1,850€)
than for the RPT (3,660€) and TAU (3,100€) groups,
reverting the situation that was found at baseline.
Outcomes
Table 4 also shows the descriptive statistics of the EQ-5D
utility and EQ VAS as well as of QALY based on the
EQ-5D utility at follow-up. Utility scores for all of the
groups increased from an average of 0.40 to an average of
0-50-0.60, with individuals in the CBT group showing the
highest scores (small differences that were not statistically
significant). A similar situation was found for the EQ VAS,
for which the three groups presented similar values at
baseline (approximately 45), but for which the CBT group
reported better results than the other groups at follow-up
(approximately 60). We can observe that all of the groups
showed improvement in their EQ-5D indicators at follow-
up. QALYs at follow-up, calculated for the 6-month inter-
vention period, were found to be similar for all groups,
with no significant differences.
Cost-utility analyses
Societal perspective
Table 5 shows the ICERs for the comparison of the three
treatment groups. As we explained earlier, the main ana-
lysis focuses on the sample of “Completers” (N = 152);
we also performed two alternative sensitivity analyses by
using the ITT sample, which includes all of the patients
assessed at baseline (N = 168) and the PPA sample (N = 154),
which excludes the 16 individuals who did not attend all
nine CBT sessions.
The analysis of completers suggests that CBT is more
cost-effective than TAU and RPT, as its incremental cost
is significantly less than zero in both cases (approxi-
mately −2,100€ for CBT versus TAU and −2,400€ for CBT
versus RPT), with the incremental effect on QALYs not
being significant; however, they were very close to a 95%
level in both cases. These findings are robust to different
specifications of the sample, whether using the ITT-based
or the PPA-based approach.
Looking at the Net-Benefit (NB) curves plotted in
Figure 2, we can see that the Net Monetary Benefit
(NMB) and its 95% CIs for the CBT intervention are
greater than zero at all hypothetical levels of willingness-
to-pay (WTP) included.When looking at the comparison between RPT and
TAU, findings from the completers’ analysis did not sup-
port the cost-effectiveness of the FDA-recommended
intervention, as the average incremental effect for QALY
was negative. The NMB for the RPT versus TAU com-
parison was negative at all WTPs, although the upper
confidence interval was found to be consistently greater
than zero. Looking at the related CEACs (Figure 3), we
can see that at a WTP of 40,000€, RPT has a probability
of only approximately 30% to be more cost-effective
than TAU.
When using the EQ VAS as an outcome, the incre-
mental cost remained significant, with an average value
of −2,100€ for CBT versus TAU and approximately −2,400€
for CBT versus RPT. In this case, the incremental effect
on EQ VAS was also found to be significant, with an aver-
age of approximately 3.5 points on the VAS (CBT versus
RPT). The results found for this outcome reinforce the
findings for QALYs. In the case of RPT versus TAU, we
can see that the incremental cost is not significantly differ-
ent from zero, but the incremental effect is greater than
zero for all the three analyses (Completers, ITT, and PPA),
which means that the medication treatment is able to im-
prove HRQoL significantly with respect to usual care and
is also likely to be cost-effective. The ICER was estimated
at 120 for the completers’ analysis, estimated at 53 for the
ITT analysis, and found to be 68 for the PPA case.
NB curves present a NMB consistently greater than
zero; therefore, the analysis suggests that CBT is cost-
effective against RPT and TAU at all the hypothesized
WTP levels (see Figure 4). In Figure 5, we plotted the
CEAC for RPT versus TAU, which suggests that the
intervention is also likely to be cost-effective because of
very small levels of WTP.
Healthcare perspective
The cost-effectiveness results from the healthcare per-
spective displayed in Table 6 were obtained by consider-
ing only the “direct healthcare costs”, including all the
health and social care service uses, medications and
intervention costs and excluding indirect costs. The
findings are consistent with what has been found in the
societal perspective. In particular, CBT has been found
to be cost-effective with respect to TAU and with re-
spect to RPT in the completers’ analysis and in the sen-
sitivity analyses, when considering EQ-5D based QALYs
and EQ VAS. By using EQ-5D-based QALYs as the out-
come, we found that TAU dominates RPT when using
the completers’ analysis perspective, whereas in the
ITT and PPA cases, ICERs were set to approximately
100,000€, which is well above established cost-effectiveness
thresholds.
When using EQ VAS as the outcome, we found that
the incremental cost is not significantly different from
Table 5 Incremental cost-effectiveness ratios, societal perspective, 0 to 6 months
Incremental cost Incremental effect ICER
Mean; (95% bootstrap CI) Mean; (95% bootstrap CI)
CBT versus TAU
Completers (N =152)
QALY (EQ-5D) −2,061.9 −3,168.9 −954.9 0.01 −0.00 0.03 CBT dominant
EQ VAS −2,073.2 −3,179.8 −966.6 6.19 3.63 8.75 CBT dominant
ITT (N =168)
QALY (EQ-5D) −2,158.8 −3,357.1 −960.5 0.02 −0.00 0.03 CBT dominant
EQ VAS −2,163.9 −3,363.8 −964.0 6.33 3.62 9.07 CBT dominant
PPA (N =154)
QALY (EQ-5D) −2,368.9 −3,599.1 −1,138.6 0.02 −0.00 0.03 CBT dominant
EQ VAS −2,372.4 −3,604.8 −1,140.0 6.58 3.83 9.33 CBT dominant
CBT versus RPT
Completers (N =152)
QALY (EQ-5D) −2,386.9 −3,485.4 −1,288.3 0.01 −0.00 0.03 CBT dominant
EQ VAS −2,393.9 −3,495.2 −1,292.6 3.52 1.13 5.90 CBT dominant
ITT (N =168)
QALY (EQ-5D) −2,304.7 −3,326.6 −1,282.7 0.01 −0.00 0.03 CBT dominant
EQ VAS −2,307.8 −3,331.4 −1,284.2 3.61 1.08 6.15 CBT dominant
PPA (N =154)
QALY (EQ-5D) −2,550.3 −3,624.9 −1,475.7 0.01 −0.00 0.03 CBT dominant
EQ VAS −2,552.7 −3,631.5 −1,473.9 3.93 1.35 6.51 CBT dominant
RPT versus TAU
Completers (N =152)
QALY (EQ-5D) 324.9 −894.8 1,544.7 −0.00 −0.02 0.01 TAU dominant
EQ VAS 320.7 −894.3 1,535.6 2.67 0.56 4.79 120
ITT (N =168)
QALY (EQ-5D) 145.9 −1,150.7 1,442.5 0.00 −0.01 0.02 79,071
EQ VAS 143.9 −1,150.8 1,438.6 2.72 0.42 5.02 53
PPA (N =154)
QALY (EQ-5D) 181.4 −1,127.9 1,490.7 0.00 −0.01 0.02 137,161
EQ VAS 180.3 −1,127.3 1,487.9 2.65 0.36 4.94 68
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zero, there are hints that the RPT may be cost-effective
with respect to usual care. These findings remain con-
sistent when observing at the sensitivity analyses that
were implemented, with ICERs ranging from 63 to 107.
Discussion
This article extends our previous findings [23], demon-
strating for the first time that a group-based form of
CBT is more cost-effective for the treatment of FM than
usual care and FDA-recommended drugs. The results of
the economic evaluation can be summarized as follows:
As expected, FM syndrome is associated with high
healthcare and societal costs, which is in accordance
with several previous studies conducted across different
FM samples from different countries [5,15]. Focusing onSpain, the baseline evaluation indicated that our FM pa-
tients from Aragon produced higher healthcare costs
(1,940€) and sick-leave costs (810€), on average, than
those reported by Sicras-Mainar et al. [46] in Catalonia
(healthcare costs = 1,677€ and sick-leave costs = 815.8€);
of note is the difference in timeframes (6-month period
versus 12-month period). The disparities in costs between
both Spanish studies might be due to the inclusion of a
different range of health care services or to structural
differences in the health care systems of these Spanish
regions but are not likely to be caused by significant differ-
ences in functional status, given that our participants, as
reported in a previous article [23], were apparently less
impaired (Alda et al. [23]: Fibromyalgia Impact Question-
naire score = 65.6 versus Sicras-Mainar et al. [46]: Fibro-
myalgia Impact Questionnaire score = 71.7).
-
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Figure 2 Net-benefit curves, societal perspective; effectiveness measured on the EQ-5D based QALYs. Dashed lines represent 95%
confidence intervals.
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http://arthritis-research.com/content/16/5/451The QALY differences between the CBT group and
the RPT and TAU groups observed in our sample (0.02
and 0.01, respectively) were smaller than those previ-
ously reported in economic evaluations of nonpharma-
cologic treatments (for example, Luciano et al. [21]:
QALY difference in usual care plus psycho-education
versus usual care = 0.12; Gusi and Tomás-Carús [21]:
QALY difference in usual care plus exercise versus usual
care = 0.13). Any clinical interpretation (for example,
greater effectiveness of psycho-education or exercise com-
pared with CBT) of the differences might be considered
speculative.0
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Figure 3 Cost-effectiveness acceptability curve: RPT versus TAU; societaAt the 6-month follow-up, CBT was dominant from
both healthcare and societal perspectives compared with
RPT and TAU. The examination of the NB curves (with
the CI curves lying above the x-axis) permits us to con-
clude that the CBT intervention might be considered
cost-effective, not only in our country, but also for any
European or North-American policymaker taking current
country-specific investment ceilings into account (for ex-
ample, Netherlands = €30,000/QALY; UK= £30,000/QALY;
USA = $60,000/QALY).
Our study is thought to be the first that supports CBT
as a cost-effective treatment option for FM patients, as0000 60000 70000 80000 90000 100000
l perspective; effectiveness measured on the EQ-5D-based QALYs.
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care and FDA-recommended drugs. Findings were con-
sistent by using EQ-5D based QALYs and EQ VAS as
outcomes and from societal and healthcare perspectives.
Moreover, the robustness of the results was confirmed
by exploring the variation in methodologic approaches
(ITT and PPA sensitivity analyses). In the current con-
text of the economic crisis in Spain, in which the health-
care system has scant resources to attend to patients
with chronic pain, we believe that the findings of this full
economic evaluation might be interesting for policy-
makers. Bearing in mind the present data and the results
recently published by Luciano et al. [22] regarding the0
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Figure 5 Cost-effectiveness acceptability curve: RPT versus TAU; socielong-term cost-utility of a 2-month psycho-educational
program compared with usual care, it might be advisable
to establish an IAPT program (Improving Access to
Psychological Therapies program) in Spain for patients
with chronic pain conditions, like the program that
already exists in the UK for patients with common mental
health problems [47].
Notwithstanding this, although our CBT program has
proven to be cost-effective, policymakers will need fur-
ther information concerning the investment needed to
train new CBT therapists. What would be the cost of
implementing group CBT in everyday medical practice?
Currently, not all first-line clinicians (GPs and nurses) or0000 60000 70000 80000 90000 100000
ional point on the EQ-VAS scale
tal perspective; effectiveness measured on the EQ VAS scale.
Table 6 Incremental cost-effectiveness ratios, healthcare perspective, 0 to 6 months
Incremental cost Incremental effect ICER
Mean; (95% bootstrap CI) Mean; (95% bootstrap CI)
CBT versus TAU
Completers (N =152)
QALY (EQ-5D) −1,577.6 −2,601.8 −553.4 0.01 −0.00 0.03 CBT dominant
EQ VAS −1,583.8 −2,606.9 −560.7 6.19 3.63 8.75 CBT dominant
ITT (N =168)
QALY (EQ-5D) −1,632.6 −2,744.6 −520.7 0.02 −0.00 0.03 CBT dominant
EQ VAS −1,635.0 −2,747.6 −522.3 6.33 3.59 9.07 CBT dominant
PPA (N =154)
QALY (EQ-5D) −1,773.5 −2,924.9 −622.1 0.02 −0.00 0.03 CBT dominant
EQ VAS −1,775.1 −2,927.6 −622.7 6.58 3.83 9.33 CBT dominant
CBT versus RPT
Completers (N =152)
QALY (EQ-5D) −1,866.8 −2,917.6 −816.0 0.01 −0.00 0.03 CBT dominant
EQ VAS −1,870.8 −2,921.6 −819.9 3.52 1.13 5.91 CBT dominant
ITT (N =168)
QALY (EQ-5D) −1,804.0 −2,786.7 −821.3 0.01 −0.00 0.03 CBT dominant
EQ VAS −1,805.4 −2,788.6 −822.2 3.61 1.08 6.15 CBT dominant
PPA (N =154)
QALY (EQ-5D) −1,972.8 −3,008.2 −937.5 0.01 −0.00 0.03 CBT dominant
EQ VAS −1,973.7 −3,011.3 −936.1 3.93 1.35 6.52 CBT dominant
RPT versus TAU
Completers (N =152)
QALY (EQ-5D) 289.2 −858.1 1,436.5 −0.00 −0.02 0.01 TAU dominant
EQ VAS 287.0 −857.3 1,431.2 2.67 0.55 4.79 107
ITT (N =168)
QALY (EQ-5D) 171.4 −1,037.3 1,380.0 0.00 −0.01 0.02 98,434
EQ VAS 170.4 −1,037.1 1,377.9 2.72 0.42 5.02 63
PPA (N =154)
QALY (EQ-5D) 199.3 −1,023.0 1,421.6 0.00 −0.01 0.02 107,697
EQ VAS 198.6 −1,022.6 1,419.7 2.65 0.35 4.94 75
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tologists, and so on) in Spain have experience or training
in group-based forms of CBT. Moreover, it is well
known that certain factors, such as the therapist’s level
of expertise, may account for the psychological improve-
ments observed after psychological interventions. Find-
ing clinicians who are well-trained in CBT and who have
experience in group psychotherapy is not an easy task.
In our opinion, future studies should model the long-
term impact of CBT training on cost-effectiveness.
When comparing RPT and TAU, we found evidence
that the former option is cost-effective, but only when
using EQ VAS as an outcome. When looking at the ITT
analysis from the societal perspective, we found an ICER
of approximately 80,000€ that could be interesting for
policymakers, although it is far from the commonlyadopted thresholds. At this point, it is important to indi-
cate that the GPs of patients included in the TAU group
had received the Guide for the Treatment of FM in Pri-
mary Care elaborated by the Aragonese Health Service,
which recommends pregabalin and duloxetine as the first
pharmacologic treatment option. Indeed, of the 49 pa-
tients in the TAU group that were followed up for eco-
nomic evaluation at 6 months, 43 (88%) had taken
anticonvulsants (25 pregabalin) and 40 (82%), antidepres-
sants (19 duloxetine), throughout the study. This aspect
could explain the nonsignificant differences in costs and
in the effectiveness between the RPT and TAU groups.
From our point of view, the modest and uncertain su-
periority of FDA-recommended drugs over usual care is
not surprising. Although a network meta-analysis [48]
indicated the significant efficacy of pregabalin and SNRIs
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treatment of FM, recent observational studies with large
samples have seriously questioned their efficacy in routine
practice. One such study is REFLECTIONS (Real World
Examination of Fibromyalgia: Longitudinal Evaluation of
Costs and Treatments) [49], a prospective 12-month
observational study of adult patients with fibromyalgia
(N = 1,700) who started a new pharmacologic treatment
among four medication cohorts (pregabalin, duloxetine,
milnacipran, and TCAs). Patients observed reported statis-
tically significant but nonclinically relevant improvements
from baseline to each follow-up visit. Wolfe et al. [50] ex-
amined the changes in pharmacologic therapies that have
occurred over the last decade in a wide sample of adult
FM patients (N = 3,123). Regarding the effect of treatment
with FDA-recommended drugs on FM outcomes, the au-
thors observed that the changing patterns of FM pharma-
cotherapy (from nonsteroidal antiinflammatory drugs and
opioids to FDA drugs) did not change the outcomes of
pain, fatigue, or functional status. In other words, switch-
ing to FDA-recommended drugs (which are more expen-
sive) did not result in clinically relevant benefits.
Some strengths of the present work should be high-
lighted: the use of an RCT design with a long follow-up
period that permitted the capture of changes in costs
and outcomes; the economic evaluation that followed
the recent CHEERS statement [28] for reporting eco-
nomic evaluations of health interventions; a comprehen-
sive interpretation and reporting of data that provides
not only statistical significance tests but also addresses
the associated uncertainty; additionally, as we mentioned
earlier, Bernardy et al. [14] assigned a high score to our
trial (7 points) by using Yates rating scale [29], which is
indicative of the considerable treatment quality; finally,
the usual care condition (TAU) reflects current clinical
practice in the context of public health care in Aragon
(Spain), providing a meaningful comparison to deter-
mine the added value of the CBT group intervention and
its potential inclusion in future clinical guidelines in this
Spanish region. Nonetheless, our findings require replica-
tion in other Spanish regions or European countries before
firm conclusions can be established regarding the super-
iority of group CBT compared with FDA-recommended
treatment and usual care.
We acknowledge the following study limitations and
shortcomings; first, it is under debate whether the use of
EQ-5D is appropriate in the economic evaluation of psy-
chological treatments because it represents a generic
measure of health status, with one of its dimensions cap-
turing a psychological construct (anxiety/depression).
However, according to Onrust et al. [51], if a participant
reports experiencing “extreme problems” on anxiety/de-
pression without any other health problems, the health
status would be evaluated as “poor”. Therefore, only byreducing the mental health problems from “extreme” to
a better outcome, psychological treatments would be
able to improve patients’ EQ-5D utility score. Further-
more, although medical procedures different from psy-
chological treatments may be able to give a substantial
improvement in QALYs, their associated costs are usu-
ally much higher as well. Psychological treatments do
not need to produce large changes in QALYs to be cost-
effective. Overall, although we agree with the remarks
from Onrust et al. [51], we add that our case seems
more favorable, as CBT intervention was associated both
with improvements in QALYs (although nonsignificant)
and with statistically significant reductions in direct and
indirect costs.
Second, among the other limitations, we can mention
the lack of an active nonpharmacologic control group.
We have not compared the cost-effectiveness of CBT with
other second- or third-generation psychological treat-
ments and nonpharmacologic options that are available in
a group format and that have proven to be effective for
improving the functional status and quality of life of FM
patients, such as Acceptance and Commitment Therapy
[52], Mindfulness-Based Stress Reduction [53], or aerobic
exercise [54]. In our opinion, future RCTs should compare
the cost-effectiveness of CBT with other active nonphar-
macologic control conditions that are equivalent to the
CBT intervention in therapy time and therapist allegiance.
Indeed, we think that the lack of control over therapist al-
legiance is one of the main flaws of the current RCT. Ac-
cording to Nuesch et al. [11], a combination of pregabalin
or SNRIs, as pharmacologic interventions, and multi-
component therapy, aerobic exercise, and CBT, as non-
pharmacologic interventions, seem most promising for
the management of FM symptoms. From our point of
view, it might have been very interesting to examine the
effectiveness and cost-effectiveness of a combined therapy
(for example, CBT as add-on to FDA-recommended drugs)
compared with either of our treatments alone [55].
Third, direct costs were most likely underestimated in
our study because of the absence of direct non-healthcare
costs (for example, patients’ travel costs to the healthcare
center or temporary hired caregivers). Similarly, regarding
indirect costs, we did not assess productivity losses associ-
ated with reduced efficiency at work (absenteeism) and
with unpaid work (for example, household work) because
methodologic difficulties are involved in measuring these
losses, and the size of the difference between study groups
was expected to be minimal. Benefit payments for disabil-
ity or unemployment (transfer costs), included in some
cost-of-illness studies, were excluded from our economic
evaluation, given that they represent an accounting cost to
the government, but not to the society as a whole.
Fourth, between-group differences in treatment ex-
pectations and treatment credibility were not assessed at
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internal validity. Smeets et al. [56] demonstrated that
chronic lower-back-pain patients' initial expectations and
credibility about the benefits of pain treatment had an in-
fluence on the final treatment outcome. In our opinion,
future studies should address the predictive capacity of
treatment expectations and treatment credibility on the
cost-effectiveness results.
Fifth, another limitation arises from the fact that we
used economic tariffs instead of unit costs because these
are not published unit costs in Spain. Economic tariffs
may differ slightly from real unit costs.
Finally, some previous studies have involved family
members in the psychological treatment of children/ado-
lescents with chronic conditions, yielding promising re-
sults [57]. In our study, spouses/significant others of the
CBT participants were not included in the treatment
(only a minimal participation of spouses in session 7).
Future studies might analyze whether involving spouses
or significant others in group CBT for FM syndrome is
more effective than standard group CBT.
Conclusions
In summary, the results of the present work support that
group CBT as a stand-alone intervention is cost-effective
compared with FDA-recommended drugs and usual
care. Therefore, a wider implementation of CBT pro-
grams in group format for FM patients within the public
provision of healthcare in Spain is recommended.
Endnotes
aAlda et al. [23]: CBT significantly decreased global pain
catastrophizing (primary end point) at the 6-month
follow-up examination with effect sizes of the Cohen
d = 0.73 and 1.01 compared with RPTand TAU, respectively.
CBT was also more effective than RPT and TAU at in-
creasing pain acceptance, functional status, and HRQoL.
No differences were noted among the three treatments
with regard to pain and depression.
bAlthough the cost-utility analysis was not described in
the ISRCTN register (http://www.controlled-trials.com/
ISRCTN10804772/), it was planned a priori. The analysis
strategy of the economic evaluation was briefly explained
in the study protocol published by García-Campayo and
collaborators [25].
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